Compare · AMGN vs FLAG
AMGN vs FLAG
Side-by-side comparison of Amgen Inc. (AMGN) and First Light Acquisition Group Inc. (FLAG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and FLAG operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $129.07B, about 456.7x FLAG ($282.6M).
- Over the past year, AMGN is up 21.6% and FLAG is up 0.0% - AMGN leads by 21.6 points.
- AMGN has hit the wire 9 times in the past 4 weeks while FLAG has been quiet.
- AMGN has more recent analyst coverage (25 ratings vs 0 for FLAG).
- Company
- Amgen Inc.
- First Light Acquisition Group Inc.
- Price
- $344.50-1.18%
- $27.42+268.55%
- Market cap
- $129.07B
- $282.6M
- 1M return
- -2.63%
- +0.00%
- 1Y return
- +21.63%
- +0.00%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NYSE
- IPO
- 1983
- 2021
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
First Light Acquisition Group Inc.
First Light Acquisition Group, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is headquartered in Reston, Virginia.
Latest AMGN
- AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS
- Amgen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
- SEC Form DEFA14A filed by Amgen Inc.
- Canaccord Genuity initiated coverage on Amgen with a new price target
- SEC Form DEFA14A filed by Amgen Inc.
- SEC Form DEFA14A filed by Amgen Inc.
- SEC Form DEF 14A filed by Amgen Inc.
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
- Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Latest FLAG
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- First Light Acquisition Group Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by First Light Acquisition Group Inc.
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- SEC Form SC 13G/A filed by First Light Acquisition Group Inc. (Amendment)
- First Light Acquisition Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- SEC Form S-1/A filed by First Light Acquisition Group Inc. (Amendment)